Argent BioPharma: A Hidden Gem traded Under $12M–Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective treatment often feels like navigating an endless maze. These individuals, about 30% of the epilepsy community, live with seizures that persist...
GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APAC
GCCL is committed to customer success, emphasizing quality control at every stage—from analysis consulting and sample processing to data management—ensuring efficient clinical trials and research analyses. SAN ANTONIO, Feb. 6, 2025 /PRNewswire/ -- Frost & Sullivan recently assessed the clinical sample analysis services industry and, based on its findings, recognizes Global Clinical Central Lab (GCCL)...
Datasea Pre-Announces Second Quarter Revenue of $20.5 Million, up 81% Year-over-Year
Gross Profit achieved a 310% Increase Year-over-Year BEIJING, Feb. 5, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), a Nevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced that its revenue for the second quarter of fiscal year 2025, ended December 31,...
Actinogen announces new and unique nonproprietary name of ’emestedastat’ for Xanamem
Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem®/UE2343 once-a-day small molecule in accordance with...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC Serplulimab has now been approved in China, Europe, and several Southeast Asian countries, benefiting over 90,000 patients SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- Shanghai...
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk...
From 0 to 100 Trillion: The Rise of Sanyou Bio’s Intelligent Molecule Library
SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a decade of relentless effort — growing from weakness to strength — gradually building a vast and advanced technological system that paves...
AI & Genomics Advances Bring New Hope to Lung Cancer Burden in Asia
SINGAPORE, Feb. 5, 2025 /PRNewswire/ -- Asia is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1). Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection and treatment outcomes. However, only the highest-risk population (heavy smokers) is advised...
Aussie sleeptech firm unveils breakthrough test
MELBOURNE, Australia, Feb. 5, 2025 /PRNewswire/ -- Australian medical technology company Optalert has revealed a breakthrough test for sleep issues, expanding access to sleep health technologies for millions of Australians. The simple test is conducted within 10 minutes on a smartphone, making it exceptionally accessible. It relies on a unique biomarker discovered by Optalert – as people with sleep issues...
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the latest developments and trends in healthcare technology in Taiwan. China Medical University (CMU) and Healthcare System unveiled groundbreaking advancements in AI-driven drug discovery and...
